The Institute of
Cancer Research- It is one of The world’s most influential
cancer research institute is . It gives intellectual instructions and trains the next generation of
cancer researchers and clinicians and also to make discoveries that defeat
cancer. They research on differences between
cancer. The Institute of
Cancer Research has ranked first in Times Higher
Education League table of universities research from Research Excellence Frame Work. Research Excellence Frame Work is the leading academic institution in UK.
The Institute of
Cancer Research (ICR) was founded in 1909 and it joined the University of London in 2003 as a research department of Royal Marsden Hospital. It has been responsible for a number of breakthrough discoveries. It is affiliated to University of London. The ICR provides both postgraduate degree programme and research degrees and currently has around 340 students. ICR is the largest comprehensive
cancer center in Europe including the Royal Marsden Hospital. The ICR receives its external grant funding from the government body the Higher
Education Funding Council for England and from charities including the
Cancer Research UK, Wellcome Trust, Breakthrough Breast
Cancer and
Leukaemia and
Lymphoma Research. The ICR also runs a number of campaigns and fundraising appeals which helps to support a variety of
cancer research projects.
The ICR continues it’s research focused into three main research themes: Genetic Epidemiology, Molecular
Pathology and Therapeutic development These areas of research are essential for the development of personalized
cancer medicine. The ICR has started work on a £20 million Centre for
Cancer Imaging that will bring experts together in a range of different imaging techniques who will work together developing better
cancer diagnostic and treatment techniques.
Scientist at the ICR were serving in the development of one of the world’s most widely used anti-cancer drugs. During 1980’s, scientists of ICR for the treatment of colon and other cancers, developed a drug active. In 1994 an ICR team was led by Michael Stratton and he discovered the BRCA2 gene, which was been linked to breast cancer, prostate
cancer and ovarian
cancer. In june 2009 “The phase 1 trial” of olaparib was found that tumors will shrank for more than half of patients with BRCA1 and BRCA2 mutations and moreover it is believed that the drug may also be useful in other patients whose
cancer it is linked to an error in their
DNA repair pathway. In 1990 Chester Beatty Laboratory extended and redeveloped to incorporate the Breakthrough Breast
Cancer Research Center, which was opened by HRH The Prince of Wales. In the 5 years from 2000 to 2005, the ICR developed on average two
drug development candidates per year. In laboratory experiments, ICR scientists also found that the drug reduced the growth of
brain tumor, it decreased the growth of ovarian tumors and in other studies, it was active against cell lines derived from other human cancers.
Last Updated on: May 20, 2025